-
MenuBack
-
PRODUCTS
-
-
-
-
-
Products
-
-
-
mRNA
-
saRNA
-
-
-
HYPE-293 Superior Grade
HYPE-293 Superior Grade
Identic to HYPE-293 with extensive quality controls for preclinical trial use.See it
-
-
-
mRNA
-
-
Information
-
Kits mRNA
-
-
-
custom mrna
Custom mRNA Synthesis service
Looking for a custom-designed mRNA?Get a Quote
Our expert product support team is at your service for your special requests.
-
-
-
custom mrna
Custom saRNA Synthesis service
Looking for a custom-designed saRNA?Get a Quote
Our expert product support team is at your service for your special requests.
-
-
-
LNP
-
-
Information
-
-
-
custom lnp
Custom LNPs service
Looking for a custom-designed LNP?Get a Quote
Our expert product support team is at your service for your special requests.
-
-
-
TECHNOLOGIES
-
-
Technologies
-
Technologies
-
Technologies
-
Technologies
-
Technologies
-
Technologies
-
-
-
Applications
-
Applications
-
Applications
-
Applications
-
Applications
-
Applications
-
-
-
TECHNICAL RESOURCES
-
-
Posters & Publications
-
-
Scientific Newsletters
-
TRANSFECTION TIPS & FAQ
-
-
-
PROTOCOLS - MSDS - RESULTS
-
Catalogue (PDF)
-
-
-
ORDER
-
-
page order
-
-
-
page order
-
-
-
page order
-
-
-
ABOUT US
-
-
Compagnie
-
Compagnie
-
-
-
Compagnie
-
Compagnie
-
-
-
Compagnie
-

saRNAs
Self-amplifying RNAs (saRNAs), also known as RNA replicons, represent a next-generation RNA platform for vaccines and gene expression studies. Their advantage over conventional mRNA vaccine platforms relies on the viral replication machinery, which amplifies the mRNA of the encoded gene of interest within target cells. In recent years, saRNA vaccines have been clinically tested with the hope of reducing the vaccination dose compared to the conventional mRNA approach. RNA replicons induce potent humoral and cellular responses with few adverse effects upon a minimal, single-dose immunization. Delivery of replicons is achieved with virus-like replicon particles (VRPs), or in nonviral vehicles such as liposomes or lipid nanoparticles (LNPs).
OZB saRNAs have been designed to produce high expression level of protein with enhanced length of duration. These self-amplifying RNAs (saRNAs) are stabilized with 5’ Cap 1 structure and 3’ poly(A) tail and are optimized to yield improved stability & performance. They are either unmodified, or modified with 5-methyl-Cytidine (m5C replaces U) to reduce innate immune responses.